News & Updates

FMT bodes well for AMR

27 May 2025 by

The PROFIT trial turns waste into gains by showing how faecal microbiota transplantation (FMT) can combat antimicrobial resistance (AMR) in patients with liver cirrhosis.

FMT bodes well for AMR

27 May 2025

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

26 May 2025 by

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

26 May 2025

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

26 May 2025

The glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) dual agonist HEC88473 demonstrates an acceptable safety profile and potential efficacy in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

26 May 2025

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025 by

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

19 May 2025 by

Treatment with resmetirom improves liver stiffness, fibrosis biomarkers, and risk scores for clinically significant portal hypertension (CSPH) in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis at 2 years, according to a study.

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

19 May 2025

Does long-term albumin therapy prolong survival in cirrhotic patients?

18 May 2025 by

Long-term human albumin (LTA) therapy among cirrhotic patients with existing or prior ascites and acute decompensation results in improved transplant-free survival (TFS), mortality, and disease-related complications, according to the results of the PRECIOSA trial.

Does long-term albumin therapy prolong survival in cirrhotic patients?

18 May 2025

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

Exposure to angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent mortality among patients with cirrhosis, a study has shown.

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025 by

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

New drug applications approved by US FDA as of 1-15 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

News & Updates

Filter by Specialty:

Specialty:

FMT bodes well for AMR

FMT bodes well for AMR

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

Linerixibat quells cholestatic itch in PBC, enabling better sleep

Linerixibat quells cholestatic itch in PBC, enabling better sleep

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Does long-term albumin therapy prolong survival in cirrhotic patients?

Does long-term albumin therapy prolong survival in cirrhotic patients?

ACE-I/ARB use helps avert death in cirrhosis patients

ACE-I/ARB use helps avert death in cirrhosis patients

TAF prophylaxis prevents mother-to-child transmission of HBV

TAF prophylaxis prevents mother-to-child transmission of HBV

Another win for semaglutide: Improved outcomes in MASH with fibrosis

Another win for semaglutide: Improved outcomes in MASH with fibrosis

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025